Choroidal Neovascularization Market Poised to Hit $5.59 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Choroidal Neovascularization Market Size Growth Forecast: What to Expect by 2025?
The valuation of the choroidal neovascularization sector has experienced significant upward momentum lately, projected to increase from $3.88 billion in 2024 to $4.18 billion by 2025, reflecting a compound annual growth rate of 7.7%. This acceleration over the past period is fundamentally linked to several converging factors, including the increased occurrence of health issues linked to inactive living, a higher incidence of macular degeneration associated with aging, a greater number of diagnosed retinal conditions, the expanding elderly demographic, escalating expenditures on ophthalmic care, and broader accessibility through enhanced educational and diagnostic programs.

How Will the Choroidal Neovascularization Market Size Evolve and Grow by 2029?
Anticipation exists for substantial expansion within the choroidal neovascularization market over the foroming years, projecting a valuation of $5.59 billion by 2029, driven by a compound annual growth rate (CAGR) measuring 7.5%; this upward trajectory is fueled by several factors, notably heightened patient education efforts, the increased utilization of optical coherence tomography angiography, rising preference for less invasive interventions, supportive reimbursement frameworks, and an expanding elderly demographic, while key developments shaping the market outlook involve the introduction of intravitreal anti-vascular endothelial (VEGF) treatments, novel gene therapies, a greater integration of telemedicine, the progression toward combination therapies, and the tailoring of treatment regimens to individual patients.

View the full report here:
https://www.thebusinessresearchcompany.com/report/choroidal-neovascularization-global-market-report

What Drivers Are Propelling the Growth of Choroidal Neovascularization Market Forward?
The increasing occurrence of age-related macular degeneration (AMD) is projected to be the primary catalyst boosting the expansion of the choroidal neovascularization (CNV) market moving forward. AMD, a condition affecting the macula and resulting in progressive loss of central sight, predominantly impacts the elderly population. This escalation in AMD cases stems from demographics shifting towards older age, greater longevity, modifications in daily habits, inherited predispositions, and heightened susceptibility to environmental hazards. Choroidal neovascularization (CNV) plays a critical role in AMD progression, specifically in the 'wet' form, characterized by abnormal blood vessel growth under the retina which impairs sight, necessitating sophisticated interventions like anti-VEGF treatments to control CNV and decelerate AMD advancement, thereby helping patients retain their central vision. For illustration, data from the US government agency, the National Institutes of Health, indicated in September 2022 that AMD instances could climb to 300 million globally by 2040, with projections suggesting 5.4 million Americans might be dealing with the condition by 2050, underscoring why the growing incidence of age-related macular degeneration is fueling the expansion within the choroidal neovascularization market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21142&type=smp

Which Emerging Trends Are Transforming the Choroidal Neovascularization Market in 2025?
Leading firms within the choroidal neovascularization sector are prioritizing the creation of novel treatments, including photodynamic therapy, aiming to equip eye care specialists with highly accurate, effective intervention methods that enhance both the results for patients and the ease of treatment administration. Photodynamic therapy (PDT) constitutes a medical procedure where a light-sensitive compound, once exposed to a specific wavelength of light, activates to eliminate problematic or malignant cellular structures. By way of illustration, in the month of February 2023, the ML6710i photodynamic laser received clearance from the Food and Drug Administration, the United States federal regulatory body, following an announcement jointly made by Canada's Bausch & Lomb, a major healare enterprise, and Finland's Modulight, a firm specialized in biomedical technology. This particular therapeutic device received approval for conjunction with Bausch + Lomb's VISUDYNE treatment, which addresses choroidal neovascularization commonly stemming from age-related macular degeneration (AMD). This recently introduced, easily transportable ophthalmic laser facilitates a focused strategy for addressing anomalous vascular growths within the eye, thereby aiding in halting the advancement of the condition and safeguarding visual acuity.

What Are the Key Segments in the Choroidal Neovascularization Market?
The choroidal neovascularizationmarket covered in this report is segmented -

1) By Treatment Type: Anti-Angiogenic Therapy; Laser Photocoagulation; Photodynamic Therapy; Verteporfin Sodium; Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
2) By Indication: Age-Related Macular Degeneration (AMD); Diabetic Macular Edema (DME); Central Serous Chorioretinopathy (CSC); Polypoidal Choroidal Vasculopathy (PCV); Myopic Macular Degeneration (MMD); Other Indications
3) By Route Of Administration: Intravitreal; Subconjunctival; Periocular; Oral
4) By End User: Hospitals; Ophthalmology Clinics; Ambulatory Surgical Centers; Research Centers

Subsegments:
1) By Anti-Angiogenic Therapy (Anti-VEGF Therapy): Ranibizumab; Bevacizumab; Aflibercept; Pegaptanib Sodium
2) By Laser Photocoagulation: Thermal Laser Photocoagulation; MicroPulse Laser Therapy
3) By Photodynamic Therapy (PDT): Standard PDT; Low-Fluence PDT; Half-Dose PDT
4) By Verteporfin Sodium: Intravenous Administration; Combination Therapy With Anti-VEGF
5) By Ranibizumab: Monthly Dosing; As-Needed Dosing; Treat-and-Extend Regimen
6) By Bevacizumab: Off-Label Use; Compounded Intravitreal Injections
7) By Aflibercept: Fixed-Dosing Regimen; Treat-and-Extend Regimen
8) By Pegaptanib Sodium: Monotherapy; Combination Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21142&type=smp

Who Are the Key Players Shaping the Choroidal Neovascularization Market's Competitive Landscape?
Major companies operating in the choroidal neovascularization market are Pfizer Inc., Roche Holding AG, AbbVie Inc., Bayer Aktiengesellschaft, Novartis AG, Teva Pharmaceutical Industries Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Biogen Inc., Chugai Pharmaceutical Co. Ltd., Alcon Inc., Genentech Inc., Bausch + Lomb Incorporated, Samsung Bioepis Co. Ltd., Santen Pharmaceutical Co. Ltd., Apellis Pharmaceuticals Inc., Kodiak Sciences Inc., Xbrane Biopharma AB, Allergan Inc., Adverum Biotechnologies Inc., Clearside Biomedical Inc., Sylentis S.A.

What Geographic Markets Are Powering Growth in the Choroidal Neovascularization Market?
North America was the largest region in the choroidal neovascularization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the choroidal neovascularization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21142

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.